Shoaib Afzal1, Stig E Bojesen2, Børge G Nordestgaard3. 1. The Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark. 2. The Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark; The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark. 3. The Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Herlev, Denmark; The Copenhagen City Heart Study, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Herlev, Denmark. Electronic address: Boerge.Nordestgaard@regionh.dk.
Abstract
BACKGROUND: Vitamin D deficiency has been implicated as a risk factor for dementia in several cross-sectional studies. We tested the hypothesis that reduced plasma 25-hydroxyvitamin D (25[OH]D) is associated with increased risk of Alzheimer's disease (AD) and vascular dementia in the general population. METHODS: We measured baseline plasma 25(OH)D in 10,186 white individuals from the Danish general population. RESULTS: During 30 years of follow-up, 418 participants developed AD and 92 developed vascular dementia. Multivariable adjusted hazard ratios for AD were 1.25 (95% confidence interval [CI], 0.95-1.64) for 25(OH)D less than 25 nmol/L vs. greater than or equal to 50 nmol/L, and 1.29 (95% CI, 1.01-1.66) for less than the 25th seasonally adjusted 25(OH)D percentile vs. more than the 50th seasonally adjusted 25(OH)D percentile. Multivariable adjusted hazard ratios for vascular dementia were 1.22 (95% CI, 0.77-1.91) for 25(OH)D less than 50 nmol/L vs. greater than or equal to 50 nmol/L, and 1.22 (95% CI, 0.79-1.87) for less than or equal to the 50th vs. more than the 50th seasonally adjusted 25(OH)D percentile. Last, multivariable adjusted hazard ratios for the combined end point were 1.28 (95% CI, 1.00-1.64) for 25(OH)D less than 25 nmol/L vs. greater than or equal to 50 nmol/L, and 1.27 (95% CI, 1.01-1.60) for less than the 25th vs. more than the 50th seasonally adjusted 25(OH)D. CONCLUSIONS: We observed an association of reduced plasma 25(OH)D with increased risk of the combined end point of AD and vascular dementia in this prospective cohort study of the general population.
BACKGROUND:Vitamin D deficiency has been implicated as a risk factor for dementia in several cross-sectional studies. We tested the hypothesis that reduced plasma 25-hydroxyvitamin D (25[OH]D) is associated with increased risk of Alzheimer's disease (AD) and vascular dementia in the general population. METHODS: We measured baseline plasma 25(OH)D in 10,186 white individuals from the Danish general population. RESULTS: During 30 years of follow-up, 418 participants developed AD and 92 developed vascular dementia. Multivariable adjusted hazard ratios for AD were 1.25 (95% confidence interval [CI], 0.95-1.64) for 25(OH)D less than 25 nmol/L vs. greater than or equal to 50 nmol/L, and 1.29 (95% CI, 1.01-1.66) for less than the 25th seasonally adjusted 25(OH)D percentile vs. more than the 50th seasonally adjusted 25(OH)D percentile. Multivariable adjusted hazard ratios for vascular dementia were 1.22 (95% CI, 0.77-1.91) for 25(OH)D less than 50 nmol/L vs. greater than or equal to 50 nmol/L, and 1.22 (95% CI, 0.79-1.87) for less than or equal to the 50th vs. more than the 50th seasonally adjusted 25(OH)D percentile. Last, multivariable adjusted hazard ratios for the combined end point were 1.28 (95% CI, 1.00-1.64) for 25(OH)D less than 25 nmol/L vs. greater than or equal to 50 nmol/L, and 1.27 (95% CI, 1.01-1.60) for less than the 25th vs. more than the 50th seasonally adjusted 25(OH)D. CONCLUSIONS: We observed an association of reduced plasma 25(OH)D with increased risk of the combined end point of AD and vascular dementia in this prospective cohort study of the general population.
Authors: Caroline S Duchaine; Denis Talbot; Mohamed Nafti; Yves Giguère; Sylvie Dodin; André Tourigny; Pierre-Hugues Carmichael; Danielle Laurin Journal: Can J Public Health Date: 2020-02-03
Authors: Ioannis Karakis; Matthew P Pase; Alexa Beiser; Sarah L Booth; Paul F Jacques; Gail Rogers; Charles DeCarli; Ramachandran S Vasan; Thomas J Wang; Jayandra J Himali; Cedric Annweiler; Sudha Seshadri Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Cristina Gussago; Beatrice Arosio; Franca Rosa Guerini; Evelyn Ferri; Andrea Saul Costa; Martina Casati; Elisa Mariadele Bollini; Francesco Ronchetti; Elena Colombo; Giuseppina Bernardelli; Mario Clerici; Daniela Mari Journal: Endocrine Date: 2016-03-08 Impact factor: 3.633
Authors: Gleicilaine A S Casseb; Gabriela Ambrósio; Ana Lúcia S Rodrigues; Manuella P Kaster Journal: Metab Brain Dis Date: 2019-01-02 Impact factor: 3.584
Authors: Joshua W Miller; Danielle J Harvey; Laurel A Beckett; Ralph Green; Sarah Tomaszewski Farias; Bruce R Reed; John M Olichney; Dan M Mungas; Charles DeCarli Journal: JAMA Neurol Date: 2015-11 Impact factor: 18.302